Hunan Nuona Pharmaceutical Technology

Hunan Nuona Pharmaceutical Technology is a clinical-stage biotechnology company based in Changsha, China, specializing in the development of innovative radiopharmaceuticals for oncology. The company utilizes a theranostics strategy, developing paired diagnostic and therapeutic agents that target specific tumor markers such as Prostate-Specific Membrane Antigen (PSMA) and Fibroblast Activation Protein (FAP). Its lead program, NN-101, is a radionuclide drug conjugate currently in clinical trials for the treatment of metastatic castration-resistant prostate cancer. Nuona Pharma's proprietary platform focuses on optimizing chelator and linker technologies to improve the stability and biodistribution of its radioactive isotopes. The company aims to provide more precise and effective treatment options for patients with advanced solid tumors through the integration of nuclear medicine and precision oncology.